| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/29/2002 | CA2438610A1 Treatment of refractory tumors using epothilone derivatives |
| 08/29/2002 | CA2438518A1 Method of treating neurological diseases |
| 08/29/2002 | CA2438513A1 Modified anti-egfr antibodies with reduced immunogenicity |
| 08/29/2002 | CA2438504A1 Treatment of solid tumours with rapamycin derivatives |
| 08/29/2002 | CA2438318A1 Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands |
| 08/29/2002 | CA2438316A1 Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands |
| 08/29/2002 | CA2438264A1 Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands |
| 08/29/2002 | CA2438245A1 Treatment involving dkk-1 or antagonists thereof |
| 08/29/2002 | CA2438241A1 Medicinal compositions comprising diclofenac and ornoprostil |
| 08/29/2002 | CA2438235A1 Neurotransmission-associated proteins |
| 08/29/2002 | CA2437977A1 Phenethanolamine derivatives for treatment of respiratory diseases |
| 08/29/2002 | CA2437529A1 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 08/29/2002 | CA2434652A1 Type 2 cytokine receptor and nucleic acids encoding same |
| 08/29/2002 | CA2434647A1 Cubic liquid crystalline compositions and methods for their preparation |
| 08/29/2002 | CA2433348A1 Detection of compounds that modulate inflammatory responses |
| 08/29/2002 | CA2432932A1 Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| 08/29/2002 | CA2429372A1 Detection of allergen-specific ige |
| 08/29/2002 | CA2426659A1 Method for treatment of tumors using combination therapy |
| 08/28/2002 | EP1234582A1 Concomitant drugs for treating glaucoma |
| 08/28/2002 | EP1234578A2 Antitumor and antiviral medications and method for producing the same |
| 08/28/2002 | EP1234573A1 Anti-inflammatory pharmaceutical compositions and their manufacturing process |
| 08/28/2002 | EP1234188A2 Protein kinase regulation |
| 08/28/2002 | EP1234185A2 Pin1 as a marker for abnormal cell growth |
| 08/28/2002 | EP1234055A2 Genetic indicators of tobacco consumption |
| 08/28/2002 | EP1234041A2 Methods for cell screening of compounds capable of modulating the activity of ubiquitin-ligase scf complexes and their uses |
| 08/28/2002 | EP1234040A2 Hbv sequences |
| 08/28/2002 | EP1234034A1 Transfer compounds, the production and the use thereof |
| 08/28/2002 | EP1234033A2 Methods for targeting cells that express fibroblast growth receptor-3 or-2 |
| 08/28/2002 | EP1234027A1 Cytokine receptor-like polynucleotides, polypeptides, and antibodies |
| 08/28/2002 | EP1234025A1 Human enzymes of the metalloprotease family |
| 08/28/2002 | EP1233981A1 G-protein coupled receptor |
| 08/28/2002 | EP1233975A1 29 human secreted proteins |
| 08/28/2002 | EP1233951A1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| 08/28/2002 | EP1233950A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS |
| 08/28/2002 | EP1233948A1 Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
| 08/28/2002 | EP1233945A1 Heterocyclic ketone and thioester compounds and uses |
| 08/28/2002 | EP1233815A1 Use of dopamine-d3 receptor agonists for the therapy of salt-dependent hypertension |
| 08/28/2002 | EP1233790A2 A33 antigen specific immunoglobulin products in cancer therapy |
| 08/28/2002 | EP1233787A1 Product inhibiting transduction of g heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment |
| 08/28/2002 | EP1233786A2 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 08/28/2002 | EP1233781A1 Assays and therapies for latent viral infection |
| 08/28/2002 | EP1233780A1 Identification of sortase gene |
| 08/28/2002 | EP1233778A1 Stanniocalcin proteins and nucleic acids and methods based thereon |
| 08/28/2002 | EP1233766A1 Use of synergistic combinations of a nk 1? receptor antagonist and a gaba analog in psychiatric disorders |
| 08/28/2002 | EP1233765A1 TREATMENT OF EOSINOPHIL ASSOCIATED PATHOLOGIES BY MODULATING PKC-$g(d) ACTIVITY |
| 08/28/2002 | EP1233753A1 Composition and method for treatment of otitis media |
| 08/28/2002 | EP1233752A2 Radiation sensitive liposomes |
| 08/28/2002 | EP1233670A1 Nitric oxide donors for inducing neurogenesis |
| 08/28/2002 | EP0973731B1 Hydroxamic acid derivatives |
| 08/28/2002 | EP0933995A4 Method of treating endothelial injury |
| 08/28/2002 | EP0829011B1 Inhibition of amylin release |
| 08/28/2002 | EP0806956B1 Use of 5'substituted nucleosides to provide resistance in cytostatic treatment |
| 08/28/2002 | CN1089607C Immunomodulatory complex for helicobacter bacteria |
| 08/28/2002 | CN1089584C Treatment for arteriosclerosis and vitiligoidea |
| 08/27/2002 | US6441149 Isolated nucleic acids |
| 08/27/2002 | US6441137 Tie-2 ligands; tie= ?tyrosine kinase with ig (immunoglobulins) and egf (epidermal growth factor) homology domains?; tumor neovascularization |
| 08/27/2002 | US6441053 Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same |
| 08/27/2002 | US6441049 Administering compound effective to inhibit binding of an amyloid beta peptide with alpha-7 nicotinic acetylcholine receptors |
| 08/27/2002 | US6441038 Treatment of fatigue, head injury and stroke |
| 08/27/2002 | US6441027 Administering o-chloroacetylcarbamoyl fumagillol |
| 08/27/2002 | US6441026 And an alkylating agent, an antimetabolite, a spindle poison, an epidophyllotoxin, an antibiotic, an enzyme, a topoisomerase inhibitor, a platinum coordination complex, a biological response modifier or a growth factor inhibitor |
| 08/27/2002 | US6441017 Inhibitors of prenyl-protein transferase |
| 08/27/2002 | US6441009 Carboxyl pyridine derivatives chelate and inactivate the metals which can be carcinogenic or poisonous |
| 08/27/2002 | US6440998 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative |
| 08/27/2002 | US6440985 Methods for treating viral infections |
| 08/27/2002 | US6440980 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs |
| 08/27/2002 | US6440967 Combination of a GABAA alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin E |
| 08/27/2002 | US6440964 Containing antibiotics such as moxifloxacin; treating infections of microbacterium species microbacterium otitidis and microbacterium alconae |
| 08/27/2002 | US6440950 Selective and non-invasive visualization or treatment of vasculature |
| 08/27/2002 | US6440947 Coadministration of an adenosine a2 receptor agonist, e.g., adenosine and heparin or heparin-like compound to improve collateral coronary circulation in patients suffering from myocardial infarction; angiogenisis |
| 08/27/2002 | US6440938 Prevention and/or treatment of allergic conditions |
| 08/27/2002 | US6440732 Checkpoint/repair genes involved with dna repair prior to replication; aging resistance; cancer therapy |
| 08/27/2002 | US6440465 Topical composition for the treatment of psoriasis and related skin disorders |
| 08/27/2002 | US6440450 Soft chewable tablet comprising separated active ingredients |
| 08/27/2002 | US6440421 Treatment of bone disorders with adrenomedullin or adrenomedullin agonists |
| 08/27/2002 | US6440419 J chain or portion thereof linked to at least one enzyme inhibitor; specifically binds to basolateral factor; eradi-cation of metastatic or nonpolarized cells; lung, breast, colon, ovarian and prostate carcinoma and endometriosis |
| 08/27/2002 | US6440414 Fibrolase and novel acting thrombolytic agents suitable for liquid frozen state or lyophilization storage; metallo-proteinase fibrinolytic agent of seq.id no: 1, zinc stabilizer, buffer and optionally a bulking agent |
| 08/27/2002 | US6440410 Normalizing cholesterol and blood pressure; administering natural antioxidant phytochemicals found in fruits and vegetables, including polyphenols, such as chlorogenic acid and ellagic acid, and an enzyme mixture |
| 08/27/2002 | US6440407 Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 (IL-3) multiple mutation polypeptides |
| 08/27/2002 | US6440387 For decreasing blood cholesterol levels, thereby decreasing risk for developing alzheimer's disease; for post menopausal women |
| 08/26/2002 | CA2373363A1 Antitumor and antiviral medications and method for producing the same |
| 08/22/2002 | WO2002065136A2 Yeast screens for agents affecting protein folding |
| 08/22/2002 | WO2002064832A1 Method of examining allergic disease |
| 08/22/2002 | WO2002064795A2 Putative human enzymes |
| 08/22/2002 | WO2002064792A2 Molecules for disease detection and treatment |
| 08/22/2002 | WO2002064787A1 Neurotonin and use thereof |
| 08/22/2002 | WO2002064785A1 NOVEL CLOCK GENE Bmal2 |
| 08/22/2002 | WO2002064784A2 Yeast strain of saccharomyces cerevisiae with functional expression of a glut transporter |
| 08/22/2002 | WO2002064748A2 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 08/22/2002 | WO2002064742A2 Compounds effecting neuron remodeling and assays for same |
| 08/22/2002 | WO2002064635A1 2-alkylated-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
| 08/22/2002 | WO2002064629A2 Isolated human transporter proteins, nucleic acid molecules encoding them and uses thereof |
| 08/22/2002 | WO2002064626A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 08/22/2002 | WO2002064612A2 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 08/22/2002 | WO2002064550A1 Glucocorticoid receptor modulators |
| 08/22/2002 | WO2002064549A1 Ppar agonists |
| 08/22/2002 | WO2002064212A1 Method and compositions for reducing cardiac dysfunctions with a selective histamine h3 receptor agonist |
| 08/22/2002 | WO2002064210A2 Combination therapy comprising anti-diabetic and anticonvulsant agents |
| 08/22/2002 | WO2002064168A1 Targetted anti-tumor drug delivery systems |
| 08/22/2002 | WO2002064164A1 Gm-csf and/or defensin protein expression regulators in epithelial cells comprising ets transcription factor or gene encoding the same |